Human LILRB4 (ILT-3) knockout A549 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
LILRB4 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon2 and 52 bp deletion in exon2.
View Alternative Names
CD85 antigen-like family member K, CD85k, HM18, ILT-3, Immunoglobulin-like transcript 3, LILRB4, LIR-5, LIRB4_HUMAN, Leukocyte immunoglobulin like receptor subfamily B (with TM and ITIM domains) member 4, Leukocyte immunoglobulin-like receptor 5, Leukocyte immunoglobulin-like receptor subfamily B member 4, Monocyte inhibitory receptor HM18
- Sanger seq
Unknown
Sanger Sequencing - Human LILRB4 (ILT-3) knockout A549 cell lysate (AB258030)
Allele-1 : 52 bp deletion in exon2
- Sanger seq
Unknown
Sanger Sequencing - Human LILRB4 (ILT-3) knockout A549 cell lysate (AB258030)
Allele-2 : 4 bp deletion in exon2
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
ILT-3 acts as an inhibitory receptor that modulates immune responses. It is often linked with the control of T cell activation and the maintenance of immune tolerance. ILT-3 does not form part of a larger protein complex. Its inhibitory function helps in preventing overactivation of the immune system by modulating the signaling pathways necessary for immune response. This modulation occurs through ITIM (Immunoreceptor Tyrosine-based Inhibitory Motif) domains that recruit phosphatases helping in dephosphorylating key signaling proteins and aiding in downregulation of immune cell activities.
Pathways
The ILT-3 protein is involved in important immune regulatory pathways contributing significantly to the immune checkpoint pathway. It interacts with other immunoglobulin-like receptors and is known to influence pathways involving PD-1 (Programmed cell death protein 1) and CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4). By affecting these pathways ILT-3 serves as a checkpoint that ensures immune homeostasis prevents excess inflammation and influences the balance between immune activation and suppression within the body.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com